ArticleScientific reports2026
Neutrophil extracellular traps as biomarkers for predicting prognosis and chemotherapy response in colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Review
- Neutrophil extracellular traps in colorectal cancer: a paradoxical nexus of tumor defense and disease progression.Frontiers in immunology · 2026Review
- Neutrophil Extracellular Traps in Pancreatic Ductal Adenocarcinoma: A Vicious Cycle in the Tumor Microenvironment and Targeted Interventions.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer (CRC) is a prevalent malignancy with high mortality. Neutrophil extracellular traps (NETs) are implicated in metastasis and chemotherapy resistance, making them potential biomarkers for prognosis and treatment response. We extracted NETs-related genes (NRGs) from neutrophil transcriptome data derived from in vitro-treated cells and used LASSO regression to construct a NETs risk score model. Then we validated it in multiple public CRC datasets. Serum citrullinated histone H3 (CitH3) levels were measured in 146 CRC patients and 49 healthy controls by enzyme-linked immunosorbent assay (ELISA) to evaluate diagnostic and prognostic utility, as well as chemotherapy response prediction. The model demonstrated robust prognostic performance (AUC = 0.745-0.762 for 1-5 year survival), with high-risk patients exhibiting significantly reduced survival (p < 0.0001) and compromised treatment efficacy. CitH3 levels were markedly elevated in CRC patients, particularly in those with poor prognosis and chemotherapy resistance, suggesting diagnostic and predictive utility. This study establishes NETs-based risk scoring as an effective tool for CRC prognosis and treatment response prediction, while serum CitH3 emerges as a promising biomarker for diagnosis and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.